(Q54744716)

3 June 2018

title

A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. (English)

1 reference

3 June 2018

main subject

phase II clinical trial

0 references

1 reference

1 reference

9

Charles S Fuchs

1 reference

3 June 2018

author name string

Matthew H Kulke

1

1 reference

3 June 2018

Bingyan Wu

2

1 reference

3 June 2018

David P Ryan

3

1 reference

3 June 2018

Peter C Enzinger

4

1 reference

3 June 2018

Andrew X Zhu

5

1 reference

3 June 2018

Jeffrey W Clark

6

1 reference

3 June 2018

Craig C Earle

7

1 reference

3 June 2018

Ann Michelini

8

1 reference

3 June 2018

publication date

1 June 2006

1 reference

3 June 2018

Digestive Diseases and Sciences

published in

1 reference

3 June 2018

volume

51

1 reference

3 June 2018

issue

6

1 reference

3 June 2018

page(s)

1033-1038

1 reference

3 June 2018

Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

cites work

1 reference

12 December 2020

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

1 reference

12 December 2020

A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors

1 reference

12 December 2020

A Phase II trial of gemcitabine for metastatic neuroendocrine tumors

1 reference

12 December 2020

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

12 December 2020

Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group

1 reference

12 December 2020

Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors

1 reference

12 December 2020

Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor

1 reference

12 December 2020

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

12 December 2020

Treatment with cisplatin and etoposide in patients with neuroendocrine tumors

1 reference

12 December 2020

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

1 reference

12 December 2020

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

12 December 2020

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

12 December 2020

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

1 reference

12 December 2020

Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study

1 reference

12 December 2020

Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors

1 reference

12 December 2020

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

1 reference

12 December 2020

Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome

1 reference

12 December 2020

Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma

1 reference

12 December 2020

A phase II study of docetaxel in patients with metastatic carcinoid tumors

1 reference

12 December 2020

Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer

1 reference

12 December 2020

10.1007/S10620-006-8001-3

Identifiers

DOI

1 reference

3 June 2018

1 reference

3 June 2018